Details of the Drug

General Information of Drug (ID: DMJKWPZ)

Drug Name
Cefpirome
Synonyms
Cefpiroma; Cefpiroma [Spanish]; Cefpirome (INN); Cefpirome [INN:BAN]; Cefpiromum; Cefpiromum [Latin]; Cefrom; Cerfpirome; Keiten; Broact; CEFPIROME; S72Q2F09HY; cefpirome sulfate; cefpirome sulphate; (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 84957-29-9; C22H22N6O5S2; CHEBI:3503; HR 810; HR-810; NCGC00181339-01; UNII-S72Q2F09HY
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 514.6
Logarithm of the Partition Coefficient (xlogp) 0.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [1]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.9 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.7 hours [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 111.0463 micromolar/kg/day [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.9% [2]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.24 L/kg [2]
Chemical Identifiers
Formula
C22H22N6O5S2
IUPAC Name
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Canonical SMILES
CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-]
InChI
DKOQGJHPHLTOJR-WHRDSVKCSA-N
InChIKey
1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1
Cross-matching ID
PubChem CID
5479539
ChEBI ID
CHEBI:3503
CAS Number
84957-29-9
DrugBank ID
DB13682
INTEDE ID
DR2656

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Beta-lactamase (blaB) DEEAL81 BLA2_KLEPO Substrate [4]
Beta-lactamase (blaB) DEMIUB2 BLAT_ECOLX Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.